naltrexone - CISMeF

Preferred Label : naltrexone;

MeSH definition : Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.;

CISMeF synonym : lacer brand of naltrexone hydrochloride; Schering-Plough brand of naltrexone hydrochloride; schering plough brand of naltrexone hydrochloride; lamepro brand of naltrexone hydrochloride; united drug brand of naltrexone hydrochloride; orphan brand of naltrexone hydrochloride; Bristol-Myers squibb brand of naltrexone hydrochloride; bristol myers squibb brand of naltrexone hydrochloride; du pont brand of naltrexone hydrochloride; pharmazam brand of naltrexone hydrochloride; hydrochloride, naltrexone;

MeSH hyponym : trexan; antaxone; ReVia; Naltrexone Hydrochloride; celupan; EN-1639A; EN 1639A; EN1639A; Nemexin; Nalorex;

MeSH CAS label : Morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, (5alpha)-;

MeSH Related Number : 16590-41-3 (Naltrexone); naltrexone hydrochloride; Z6375YW9SF;

Registry Number MeSH : 16590-41-3;

Related CAS MeSH : Z6375YW9SF (Naltrexone hydrochloride);

Wikipedia link : https://en.wikipedia.org/wiki/Naltrexone;

Codes EINECS : 240-649-9;

Is substance : O;

UNII : 5S6W795CQM;

InChIKey : DQCKKXVULJGBQN-XFWGSAIBSA-N;

Details

Origin ID

D009271;

UMLS CUI

C0027360;

ATC code(s)
- oxycodone and naltrexone [ATC Code]
ATC code(s)
- bupropion and naltrexone [ATC Code]
- naltrexone [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Naltrexone [PCS menu]
- Naltrexone [PCS menu]
- Naltrexone [ICHI extension code]
- Naltrexone Hydrochloride [NCIt concept]
- Naltrexone hydrochloride (substance) [SNOMED CT concept]
- naltrexone hydrochloride [SNOMED Notion]
- naltrexone hydrochloride [Substance BNPC]
CISMeF manual mappings
- Naltrexone adverse reaction (disorder) [SNOMED CT concept]
- Naltrexone measurement (procedure) [SNOMED CT concept]
- naltrexone [Substance BNPC]
Currated CISMeF NLP mapping
- Naltrexone [ICD-11 Extension code]
- Naltrexone [LOINC component]
- Naltrexone [NCIt concept]
- Naltrexone (substance) [SNOMED CT concept]
- naltrexone [SNOMED Notion]
Pharmacological action(s)
- alcohol deterrents [MeSH Descriptor]
- narcotic antagonists [MeSH Descriptor]
Record concept(s)
- EN-1639A [MeSH concept]
- Naltrexone Hydrochloride [MeSH concept]
- ReVia [MeSH concept]
- antaxone [MeSH concept]
- celupan [MeSH concept]
- naltrexone [MeSH concept]
- trexan [MeSH concept]
Related MeSH Supplementary Concept(s)
- 10-ketonaltrexone [MeSH Supplementary Concept]
- 14-chloroacetylnaltrexone [MeSH Supplementary Concept]
- 17,17'-bis(cyclopropylmethyl)-6,6',7,7'-tetrahydro-4,5-4',5'-diepoxy-6,6'-(benzylimino)(7,7'-bimorphinan)-3,3',14,14'-tetrol [MeSH Supplementary Concept]
- 17-(cyclopropylmethyl)-4,5-epoxy-3,4-dihydroxy-6-((phthalaldehydecarboxamido)acetamido)morphinan [MeSH Supplementary Concept]
- 17-(cyclopropylmethyl)-7-benzyl-4,5-epoxy-3,14-dihydroxymorphinan-6-one [MeSH Supplementary Concept]
- 17-cyclopropylmethyl-3,14-dihydroxy-4,5-epoxy-6-((2'-indolyl)acetamido)morphinan [MeSH Supplementary Concept]
- 17-cyclopropylmethyl-4,5-epoxy-3,14-dihydroxymorphinan-6-one-7-spiro-2'-indan [MeSH Supplementary Concept]
- 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-5',6'-dihydro-3-methoxy-4'H-pyrrolo(3,2,1-ij)quinolino(2',1'-6,7)morphinan-14-ol [MeSH Supplementary Concept]
- 17-cyclopropylmethyl-6,7-didehydro-4,5-epoxy-8'-fluoro-5',6'-dihydro-4'H-pyrrolo(3,2,1-ij)quinolino(2',1'-6,7)morphinan-3,14-diol [MeSH Supplementary Concept]
- 17-cyclopropylmethyl-6,7-didehydro-4-hydroxy-3-methoxy-6,7-2',3'-indolomorphinan [MeSH Supplementary Concept]
- 2-hydroxy-3-methoxy-6 beta-naltrexol [MeSH Supplementary Concept]
- 3,3'-di-(N-cyclopropylmethyl-4,5-epoxy-14-hydroxymorphinan-6-one-3-yl)carbonate [MeSH Supplementary Concept]
- 3,6,14-trihydroxy-6-(2-carboxyallyl)-17-(cyclopropylmethyl)morphinan gamma-lactone 4,5-epoxide [MeSH Supplementary Concept]
- 3-acetyl-6-deoxy-6-fluoronaltrexone [MeSH Supplementary Concept]
- 3-carboxamido-4-hydroxynaltrexone [MeSH Supplementary Concept]
- 3-methoxynaltrexone [MeSH Supplementary Concept]
- 5'-acetamidinoethylnaltrindole [MeSH Supplementary Concept]
- 6 beta-hydroxynaltrexone [MeSH Supplementary Concept]
- 6'-guanidinonaltrindole [MeSH Supplementary Concept]
- 6,6'-(ethylenebis(oxyethyleneimino))bis(17-cyclopropylmethyl)-4,5-epoxymorphinan-3,14-diol [MeSH Supplementary Concept]
- 6-(2-phenylethyl)oximino naltrexone [MeSH Supplementary Concept]
- 6-(3-phenylpropyl)oximino naltrexone [MeSH Supplementary Concept]
- 6-N-methylnaltrexamine [MeSH Supplementary Concept]
- 6-bromoacetamido-6-desoxynaltrexone [MeSH Supplementary Concept]
- 6-deoxy-6-fluoronaltrexone [MeSH Supplementary Concept]
- 6-thioglycolamido-6-desoxynaltrexone [MeSH Supplementary Concept]
- 7-(2-methoxybenzylidene)naltrexone [MeSH Supplementary Concept]
- 7-(4-methylbenzylidene)naltrexone [MeSH Supplementary Concept]
- 7-(5',6'-benzo-2'-spiroindanyl)naltrexone [MeSH Supplementary Concept]
- 7-benzylidenenaltrexone [MeSH Supplementary Concept]
- ALKS 5461 [MeSH Supplementary Concept]
- BNAP compound [MeSH Supplementary Concept]
- BU10038 [MeSH Supplementary Concept]
- CNGN-TI compound [MeSH Supplementary Concept]
- HS 378 [MeSH Supplementary Concept]
- KDAN 18 [MeSH Supplementary Concept]
- KDN 21 [MeSH Supplementary Concept]
- KMN-21 compound [MeSH Supplementary Concept]
- KNT 93 [MeSH Supplementary Concept]
- N-benzylnaltrindole [MeSH Supplementary Concept]
- N-methylfunaltrexamine [MeSH Supplementary Concept]
- N-naphthoyl-beta-naltrexamine [MeSH Supplementary Concept]
- N1'-fluoroethyl-(14-formylamino)naltrindole [MeSH Supplementary Concept]
- N1'-fluoroethyl-naltrindole [MeSH Supplementary Concept]
- NAP naltrexamine [MeSH Supplementary Concept]
- NTI compound [MeSH Supplementary Concept]
- Naltrexone-Bupropion combination [MeSH Supplementary Concept]
- SDM 25N [MeSH Supplementary Concept]
- SG-II-49 compound [MeSH Supplementary Concept]
- WYE-120318 [MeSH Supplementary Concept]
- beta-funaltrexamine [MeSH Supplementary Concept]
- beta-naltrexamine [MeSH Supplementary Concept]
- beta-naltrexyl-6-ethylenediamine [MeSH Supplementary Concept]
- binaltorphimine [MeSH Supplementary Concept]
- bupropion hydrochloride, naltrexone hydrochoride drug combination [MeSH Supplementary Concept]
- chlornaltrexamine [MeSH Supplementary Concept]
- iodobenzoylnaltrexamide [MeSH Supplementary Concept]
- methylnaltrexone [MeSH Supplementary Concept]
- morphine, naltrexone combination [MeSH Supplementary Concept]
- naldemedine [MeSH Supplementary Concept]
- nalmafene 3-O-diglucuronide [MeSH Supplementary Concept]
- nalmefene [MeSH Supplementary Concept]
- naltrexamine, N(beta)-(Leu-Arg-Arg-Leu-Phe)- [MeSH Supplementary Concept]
- naltrexazone [MeSH Supplementary Concept]
- naltrexonazine [MeSH Supplementary Concept]
- naltrexone 3-glucuronide [MeSH Supplementary Concept]
- naltrexone phenyl oxime [MeSH Supplementary Concept]
- naltrexone-14-O-sulfate [MeSH Supplementary Concept]
- naltrexone-3-O-(2'-ethylbutyrate) [MeSH Supplementary Concept]
- naltrexone-3-O-valerate [MeSH Supplementary Concept]
- naltrexone-3-salicylate [MeSH Supplementary Concept]
- naltrexone-estrone azine [MeSH Supplementary Concept]
- naltrindole [MeSH Supplementary Concept]
- naltrindole 5'-isothiocyanate [MeSH Supplementary Concept]
- naltrindole benzofuran [MeSH Supplementary Concept]
- norbinaltorphimine [MeSH Supplementary Concept]
- oxycodone naltrexone combination [MeSH Supplementary Concept]
- oxymorphone-3-methoxynaltrexonazine [MeSH Supplementary Concept]
- oxymorphone-naltrexonazine [MeSH Supplementary Concept]
- oxytrex [MeSH Supplementary Concept]
- pregnenolone-naltrexone azine [MeSH Supplementary Concept]
- vivitrol [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Naltrexone [LOINC component]
- Naltrexone [ICD-11 Extension code]
- Naltrexone [NCIt concept]
- Naltrexone (substance) [SNOMED CT concept]
- Product containing naltrexone (medicinal product) [SNOMED CT concept]
- naltrexone [ATC Code]
- naltrexone [Substance BNPC]
- naltrexone [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients